Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix has submitted the last label materials to the US Food & Drug Administration (FDA) for Sofdra™ a pending prescription treatment for excessive underarm sweating. Label discussions are the final step for Botanix before the anticipated FDA approval of Sofdra and have involved product carton design and wording of information that is provided to patients and physicians about the product.
https://botanixpharma.com/wp-content/uploads/Business.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-06-12 00:23:572024-06-12 00:29:46Final Sofdra™ Labelling Discussions with FDA
In new research on Botanix, leading biotech analyst David Nayagam from E&P highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy and $0.55 price target. This increased interest in Botanix comes at a critical time, as we await the commencement of labelling discussions with the FDA – the final regulatory hurdle for Sofdra™ before expected approval in late June 2024.
Euroz Hartleys’ Seth Lizee reviews the Botanix Commercial Day Webinar and maintains a Speculative Buy recommendation with an upgraded $0.33 Price Target.
Lizee expressed increased confidence in the late June FDA approval decision and BOT’s commercial strategy.
Video is now available of the Company’s Commercial Day Webinar presented on 8 May.
The expanded commercial team provides market insights and a comprehensive update on commercial launch plans for Sofdra™, which is expected to be approved in late June 2024.
https://botanixpharma.com/wp-content/uploads/Commercial-Plan.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-05-13 22:16:282024-05-13 22:16:29Video Available | Commercial Day Webinar
Botanix Pharmaceuticals (ASX:BOT) is honoured to announce the Company’s inclusion in the ASX All Ordinaries Index. Botanix joins the ranks of the index, based on its strong performance over the last 12 months.
Botanix Chief Executive Officer, Howie McKibbon, commented:“We are humbled to acknowledge the confidence investors have shown in our company, as exemplified by our inclusion in the ASX All Ordinaries Index.”
The performance of Botanix shares has been driven by interest in the Company’s Sofpironium Bromide gel, Sofdra™, which is a topical treatment for excessive underarm sweating that is expected to receive approval from the US FDA in late June. Botanix launch preparations are well underway.
https://botanixpharma.com/wp-content/uploads/All-ordinaries.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-04-15 00:23:102024-04-15 00:23:47Botanix Included in the All Ordinaries Index
FDA Approves Sofdra™ topical gel
/in ASX Releases, Featured, Latest News, News /by Haley ChartresFinal Sofdra™ Labelling Discussions with FDA
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix has submitted the last label materials to the US Food & Drug Administration (FDA) for Sofdra™ a pending prescription treatment for excessive underarm sweating. Label discussions are the final step for Botanix before the anticipated FDA approval of Sofdra and have involved product carton design and wording of information that is provided to patients and physicians about the product.
Click here to view ASX release.
“Compelling Opportunity” | E&P Research Report
/in Featured, Latest News, News /by Haley ChartresIn new research on Botanix, leading biotech analyst David Nayagam from E&P highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy and $0.55 price target. This increased interest in Botanix comes at a critical time, as we await the commencement of labelling discussions with the FDA – the final regulatory hurdle for Sofdra™ before expected approval in late June 2024.
View E&P Report.
Euroz Hartleys Analysis | Commercial Day Webinar
/in Featured, Latest News, News /by Haley ChartresEuroz Hartleys’ Seth Lizee reviews the Botanix Commercial Day Webinar and maintains a Speculative Buy recommendation with an upgraded $0.33 Price Target.
Lizee expressed increased confidence in the late June FDA approval decision and BOT’s commercial strategy.
Click here to read the report.
Video Available | Commercial Day Webinar
/in Featured, Latest News, News, Presentations, Videos /by Haley ChartresVideo is now available of the Company’s Commercial Day Webinar presented on 8 May.
The expanded commercial team provides market insights and a comprehensive update on commercial launch plans for Sofdra™, which is expected to be approved in late June 2024.
Botanix Included in the All Ordinaries Index
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix Pharmaceuticals (ASX:BOT) is honoured to announce the Company’s inclusion in the ASX All Ordinaries Index. Botanix joins the ranks of the index, based on its strong performance over the last 12 months.
Botanix Chief Executive Officer, Howie McKibbon, commented: “We are humbled to acknowledge the confidence investors have shown in our company, as exemplified by our inclusion in the ASX All Ordinaries Index.”
The performance of Botanix shares has been driven by interest in the Company’s Sofpironium Bromide gel, Sofdra™, which is a topical treatment for excessive underarm sweating that is expected to receive approval from the US FDA in late June. Botanix launch preparations are well underway.
Click here to read today’s ASX release.